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Letters to the Editor
Switching Thienopyridines:
Hypothetical Versus Real Risks
I enjoyed reading the quality paper by Campo et al. (1) that tried
to determine whether platelet response after thienopyridines is
drug or class specific in a broad spectrum of post-stent patients.
The team should be acknowledged for the effort and for realistic
rates for low response after clopidogrel (21%), and ticlopidine
(19%). The major take-home message conveyed to the readership
is that clopidogrel-treated patients may be switched to ticlopidine
if “resistance” is determined by the platelet tests. However, the
practical implications of this idea are not obvious, may be danger-
ous, may not be supported by clinical or epidemiologic evidence,
and deserve at least some clarification and/or adjustment.
In fact, low response to clopidogrel as a major risk factor for the
worsened vascular outcomes has been suspected but never proven
to be a real clinical phenomena, especially considering that no load
75 mg clopidogrel saved 119 lives, and provided an absolute
mortality benefit after myocardial infarction in COMMIT
(Clopidogrel and Metoprolol in Myocardial Infarction Trial)
( 2 ). Also, none of the small observation studies monitor
compliance by measuring clopidogrel metabolites in plasma.
Therefore, “clopidogrel resistance” is a laboratory finding,
rather than a clinically relevant hazard unless further random-
ized evidence became available (3 ).
On the other hand, substituting clopidogrel with ticlopidine
definitely increases the bone marrow toxicity risks. Indeed, neu-
tropenia and thrombocytopenia were 2-fold higher in the ticlopi-
dine arm than in patients treated with clopidogrel in CLASSICS
(Clopidogrel Aspirin Stent International Cooperative Study) (4).
Doubled cytotoxicity rates after ticlopidine were confirmed in a
post-stent study (5) and a recent meta-analysis of 11,668 patients
(6). Therefore, the suggestion that in case of low platelet response
after clopidogrel patients should be switched to ticlopidine is not valid.
Unless there is proof that response after clopidogrel is indeed linked to
the clinical outcomes, monitoring compliance and potential tailoring
of dual antiplatelet regimens with aspirin and clopidogrel will be a
safer alternative than switching thienopyridines.
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Reply
We welcome the thoughtful comments by Dr. Serebruany to our
recent publication on clopidogrel poor responsiveness in a broad
population undergoing coronary stenting (1). Our major focus was
to assess whether clopidogrel poor responders display inadequate
platelet inhibition also after ticlopidine administration. We found
that the great majority (83%) of patients who were clopidogrel
nonresponders became responsive to ticlopidine, reaching a higher
level of platelet inhibition (platelet aggregation [PA] 69  15 vs.
44  18; p  0.01).
On the other hand, 23 patients who were responsive to
clopidogrel showed resistance to ticlopidine and correspondingly
less platelet inhibition with this drug (PA 46  15 vs. 70  15;
p  0.01).
When taken together our findings strongly suggest that poor
responsiveness to currently commercially available thienopyridines
may frequently be a drug-specific more than a class-effect mech-
anism. This conclusion holds particularly true in consideration that
in the currently recommended regimen ticlopidine at steady state
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